Amino-acetic acid heptyl ester | 55636-85-6

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Amino-acetic acid heptyl ester
• 英文别名: Glycine, heptyl ester；heptyl 2-aminoacetate
• CAS: 55636-85-6
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: TYGLWFFMKXMEAM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  8
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Amino-acetic acid heptyl ester 、 (S)-2-[{(allyloxy)carbonyl}amino]-4-(methylthio)butanoic acid 生成 N-Allyloxycarbonyl-L-methionyl-glycin-heptylester
  参考文献：
  名称：

  BRAUN, PETER;WALDMANN, HERBERT;VOGT, WALTER;KUNZ, HORST, LIEBIGS ANN. CHEM.,(1991) N, C. 165-170

  摘要：

  DOI：
• 作为产物：
  描述：

  聚甘氨酸 、 正庚醇 生成 Amino-acetic acid heptyl ester
  参考文献：
  名称：

  BRAUN, PETER;WALDMANN, HERBERT;VOGT, WALTER;KUNZ, HORST, LIEBIGS ANN. CHEM.,(1991) N, C. 165-170

  摘要：

  DOI：

文献信息

• Selective Enzymatic Removal of Protecting Groups from Phosphopeptides: Chemoenzymatic Synthesis of a Characteristic Phosphopeptide Fragment of the Raf-1 Kinase
  作者：Dagmar Sebastian

  DOI：10.1055/s-1997-1306

  日期：1997.9

  Base-labile biologically relevant phosphopeptides can advantageously be synthesized under very mild conditions and without undesired side reactions by employing the heptyl (Hep) ester as C-terminal or the phenylacetamide (PhAc) as N-terminal enzyme-labile protecting group. The lipase-mediated saponification of the heptyl ester blocking function was successfully applied in the construction of a characteristic selectively phosphorylated hydroxyamino acid fragment of Raf-1 kinase, an important member of the so-called Ras signal transduction pathway.

  通过采用庚酯(Hep)作为C-末端或苯乙酰胺(PhAc)作为N-末端酶不稳定保护基团，可以有利地在非常温和的条件下合成碱不稳定的生物学相关磷酸肽，并且没有不希望的副反应。脂肪酶介导的庚酯阻断功能皂化已成功应用于构建 Raf-1 激酶的特征性选择性磷酸化羟基氨基酸片段，Raf-1 激酶是所谓的 Ras 信号转导途径的重要成员。
• BRAUN, PETER;WALDMANN, HERBERT;VOGT, WALTER;KUNZ, HORST, LIEBIGS ANN. CHEM.,(1991) N, C. 165-170
  作者：BRAUN, PETER、WALDMANN, HERBERT、VOGT, WALTER、KUNZ, HORST

  DOI：——

  日期：——
• EP1463823A4
  申请人：——

  公开号：EP1463823A4

  公开（公告）日：2005-11-16
• METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN (EPO)
  申请人：FibroGen, Inc.

  公开号：EP1463823A2

  公开（公告）日：2004-10-06
• [EN] METHODS OF INCREASING ENDOGENOUS ERYTHROPOIETIN EPO<br/>[FR] METHODES PERMETTANT D'AUGMENTER L'ERYTHROPOIETINE ENDOGENE (EPO)
  申请人：FIBROGEN INC

  公开号：WO2003053997A2

  公开（公告）日：2003-07-03

  The present invention relates to methods for treating erythropoietin-associated conditions by increasing endogenous erythropoietin in vitro and in vivo. Methods for treating, pretreating or preconditioning, or preventing erythropoietin-associated conditions are also included. Compounds for use in these methods are provided, as are methods of identifying such compounds.